FDA warning letter · #716700
Slendid: What the FDA Letter Means for What You Pay
Operating
marketing / labeling
September 2025
Not logged
Primary source
Read the original letter on fda.gov →
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/slendid-716700-09092025
What FDA cited
Quoted verbatim from the letter dated
Read the full letter →This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://slendid.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.
- 1
“The following claim concerning compounded semaglutide and tirzepatide products appears on your website:”
- 2
““Clinically proven weight loss treatments””
- 3
“Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not.”
Process
How a warning letter proceeds
- 1
Letter issued
September 2025
- 2
15-working-day response window
FDA gives the company 15 working days to respond in writing.
- 3
Close-out, if issued
FDA may post one once it is satisfied the cited issues have been corrected.
Is Slendid still operating?
slendid.com returned a live storefront when we checked in August 2026, still selling online GLP-1 prescriptions with a client portal and a published phone number. We did not review every page on the site.
What this means for what you pay
Four words drew this letter, which is the most useful thing about it. "Clinically proven" is doing a specific job in a price comparison: it invites you to treat a cheaper compounded vial and an approved brand as interchangeable, so that the only remaining difference is the number. FDA's point is that the trials behind that phrase were run on the approved product, not on the compounded one you would be buying. That does not mean the medication does not work or that the company misled anyone deliberately — it means the phrase carries more authority than the product behind it has earned. Read the price for what it is, and read "clinically proven" as marketing copy rather than a regulatory status.
Has Slendid responded?
As of , FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Slendid failed to respond.
Sources
Other letters in this index
Maximus
marketing / labeling · Issued June 2026
Ezra
marketing / labeling · Issued June 2026
Eden
marketing / labeling · Issued June 2026
Joi + Blokes
marketing / labeling · Issued June 2026
Thrivelab
marketing / labeling · Issued June 2026
FITISH
marketing / labeling · Issued June 2026
Editorial disclaimer: An FDA warning letter is a public regulatory communication stating the agency's view. It is not a recall, a fine, a criminal charge, an injunction, or a finding that a company has broken the law.